Q1 2019 DURECT Corp Earnings Call Transcript
Good day and welcome to the DURECT Corporation First Quarter 2019 Earnings and Key Opinion Leader Call. Today's conference is being recorded.
At this time, I would like to turn the conference over to Mike Arenberg, Chief Financial Officer of DURECT. Please go ahead.
Good morning. This is Mike Arenberg, Chief Financial Officer of DURECT Corporation. Welcome to our first quarter 2019 earnings conference call. During the call, in addition to financial results, we will be reporting preliminary data from our ongoing Phase IIa clinical trial of DUR-928 in patients with alcoholic hepatitis, which we refer to as AH. We are fortunate to be joined today by 3 key opinion leaders in alcoholic hepatitis, Dr. Paul Kwo from Stanford, Dr. Steven Flamm from Northwestern and Dr. Tarek Hassanein from the University of California at San Diego.
I will provide a brief review of our financial results; and then Jim Brown, our President and CEO, will provide a business update on our programs; after which we will turn
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |